ClinicalTrials.gg
CompletedNCT02616445Updated Jan 22, 2025

Phase I MAD, Fed-Fasted, CSF Study of UE2343 in Healthy Subjects

A Phase 1 interventional study of UE2343 and Placebo in Healthy Volunteers, sponsored by Actinogen Medical. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Actinogen Medical · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether the drug UE2343, a potential treatment for Alzheimer's Disease (AD), is effective by assessing safety, tolerability, pharmacokinetics and pharmacodynamics in a Multiple Ascending Dose Study. Protocol amendments to the study will examine any food effect and determine if the drug penetrates the Blood-Brain Barrier.

Read the detailed description

Part 1 of this study is a double-blind, randomised, placebo-controlled, multiple ascending dose study to assess the safety, tolerability, PK and PD in healthy participants dosed twice daily at levels of 10, 20 and 35mg for 10 days.This part of the study will recruit 3 groups of 8 participants each.

Part 2 is a cross-over study to assess the effects of food on the PK of UE2343 in healthy participants dosed with two single doses at a level decided from Part 1. This part of the study will recruit a total of 12 participants.

Part 3 seeks to determine the PK of the UE2343 in CSF of healthy participants dosed twice daily for 4 days with a dose level determined from Part 1 and 2. This part of the study will recruit 4 participants.

Strategies to ensure adherence to the study include the requirement that participants remain at the clinical research facility for the duration of their participation in the study; drug accountability checks (i.e. reconciliation of used and unused capsules) by an independent clinical research associate; and administration of the capsules to the participant by a member of the study site team.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Xanamem
  • emestedastat
03

In context

Lead sponsor

Actinogen Medical is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to use specified
  • within specified range
  • No abnormalities in the results of laboratory evaluations at Screening and Day -1.

Exclusion criteria

Exclusion Criteria:

  • Abnormal medical history, including history of dementia
  • No significant allergic reactions
  • No prior drug or alcohol abuse
  • Use of regular prescribed medication
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Placebo comparator
    MAD Study

    Drug: UE2343 · Drug: Placebo

  • Placebo comparator
    Fed-Fasted

    Drug: Placebo · Drug: UE2343

  • Experimental
    CSF

    Drug: UE2343

Interventions

  • DrugUE2343

    * UE2343 * 10mg, 20, 35mg * twice daily for 9 days

  • DrugPlacebo

    * 10mg, 20, 35mg * twice daily for 9 days

  • DrugPlacebo

    * Cross-over study * single dose administered twice (on day 1 and day 8) * study duration 17 days

  • DrugUE2343

    * Cross-over study * UE2343 * single dose administered twice (on day 1 and day 8) * study duration 17 days

  • DrugUE2343

    * UE2343 * twice daily for 3 days * single dose on day 4

06

What researchers measure

Primary outcomes

  1. Assess Safety and Tolerability of UE2343 over 17 days including AEs, 12-lead ECGs, vital signs, Nerve conduction velocity, Labs.

    Time frame: Up to Day 17

  2. Assess the Pharmacokinetic (PK) Plasma Parameter Maximum Plasma Concentration (Cmax) of UE2343 after a single dose

    Time frame: Day 1 and Day 8

  3. Assess the Pharmacokinetic (PK) Plasma Parameter Time to Cmax (Tmax) of UE2343 after a single dose

    Time frame: Day 1 and Day 8

  4. Assess the Pharmacokinetic (PK) Plasma Parameter Area Under the Curve (AUC) of UE2343 after a single dose

    Time frame: Day 1 and Day 8

  5. Assess the Pharmacokinetic (PK) Plasma Parameter Terminal Elimination Half Life (t½) of UE2343 after a single dose

    Time frame: Day 1 and Day 8

  6. Assess PK Parameter Maximum Plasma Concentration (Cmax) of UE2343 in CSF

    Time frame: Day 4

Secondary outcomes

  1. Assess Pharmacokinetics (PK) Plasma parameter Maximum Plasma Concentration (Cmax) from time of dosing to 12 hours

    Time frame: Day 1 and Day 10

  2. Assess Pharmacokinetics (PK) Plasma parameter Time to Cmax (Tmax) from time of dosing to 12 hours

    Time frame: Day 1 and Day 10

  3. Assess Pharmacokinetics (PK) Plasma parameter Area Under the Curve (AUC) from time of dosing to 12 hours

    Time frame: Day 1 and Day 10

  4. Assess Pharmacokinetics (PK) Plasma parameter Terminal Elimination Half Life (t½) from time of dosing to 12 hours

    Time frame: Day 1 and Day 10

  5. Assess Pharmacokinetics (PK) Urine parameters (Amount of drug excreted in urine (Ae) and Ae as a % of dose) from time of dosing to 24 hours

    Time frame: Day 1 and Day 10

  6. Assess PK Parameter Maximum Plasma Concentration (Cmax) of UE2343 in CSF compared to the Cmax value obtained in plasma

    Time frame: Day 4

  7. Assess Pharmacodynamics (PD) Blood parameter Adrenocorticotropic hormone (ACTH) from baseline to end of study

    Time frame: Days 1, 10, 11, 12, 13 and 17.

  8. Assess Pharmacodynamics (PD) Blood parameter Serum Cortisol from baseline to end of study

    Time frame: Days 1, 10, 11, 12, 13 and 17.

  9. Assess Pharmacodynamics (PD) Blood parameter for Adrenal Androgens from baseline to end of study

    Time frame: Days 1, 10, 11, 12, 13 and 17.

  10. Assess Pharmacodynamics (PD) Urine parameter Urinary Free Cortisol (UFF) from baseline to end of study

    Time frame: Days 1, 10, 11 and 12

  11. Assess Pharmacodynamics (PD) Urine parameter Urinary Free Cortisone (UFE) from baseline to end of study

    Time frame: Days 1, 10, 11 and 12

  12. Assess Pharmacodynamics (PD) Urine parameter 5α-tetrahydrocortisol (5αTHF) from baseline to end of study

    Time frame: Days 1, 10, 11 and 12

  13. Assess Pharmacodynamics (PD) Urine parameter 5β-tetrahydrocortisol (5βTHF) from baseline to end of study

    Time frame: Days 1, 10, 11 and 12

  14. Assess Pharmacodynamics (PD) Urine parameter tetrahydrocortisone (THE) from baseline to end of study

    Time frame: Days 1, 10, 11 and 12

07

Study locations

1 site
  • Linear Clinical Research
    Nedlands, Western Australia 6009, Australia
08

References and documents

Publications

  • Webster SP, McBride A, Binnie M, Sooy K, Seckl JR, Andrew R, Pallin TD, Hunt HJ, Perrior TR, Ruffles VS, Ketelbey JW, Boyd A, Walker BR. Selection and early clinical evaluation of the brain-penetrant 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor UE2343 (Xanamem). Br J Pharmacol. 2017 Mar;174(5):396-408. doi: 10.1111/bph.13699. Epub 2017 Jan 25. PubMed 28012176 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Aug 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2015
First posted
Nov 30, 2015
Start
Feb 2015
Primary completionActual
Aug 2015
CompletionActual
Sep 2015
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02616445
Lead sponsor
Actinogen Medical
Collaborators
Novotech (Australia) Pty Limited, Linear Clinical Research
Responsible party
Sponsor
First posted
Nov 30, 2015
Start date
Feb 2015
Primary completion
Aug 2015
Completion
Sep 2015
Last update
Jan 22, 2025

Study contacts

Vincent Ruffles
study chair · Actinogen Medical
Janakan Krishnarajah
principal investigator · Linear Clinical Research Limited

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: UE2343

Start the discussion